Clinical possibilities of dipyridamole in neurological practice

Cerebrovascular disease (CVD) and its chronic forms are among the most common pathologies in neurological and general medical practice. The high frequency of comorbid conditions and diseases, particularly hypertension, diabetes, lipid metabolism disorders, metabolic syndrome, and others, which contribute to the development of chronic cerebral ischemia (CCI), increases the risk of stroke and dementia – threatening, disabling complications, making chronic cerebral ischemia a pressing medical and social problem. Despite the variety of subjective symptoms of CI, cognitive impairment is considered an early and reliable manifestation of the disease. In clinical practice, one disease often masks another, misdiagnosis, and sometimes overdiagnosis contribute to the loss of valuable time and the chronicity of the disease. Timely diagnosis and adequate pathogenetic therapy aimed at improving cerebral microcirculation, optimizing neuronal metabolism, and providing neuroprotection reduce the risk of developing major complications of cerebrovascular diseases and improve the quality of life of both patients and their families. Treatment for patients with CCI includes correcting stroke risk factors, normalizing blood pressure, lowering blood cholesterol levels, and administering antithrombotic and cognitive-promoting medications. According to research data, dipyridamole, which has antiplatelet, vasotropic, antioxidant, and anti-inflammatory effects, has been used successfully in CCI. With dipyridamole use, patients with CCI experience a regression in the severity of neuropsychiatric disorders and an improvement in overall well-being, as confirmed by the presented clinical case. Non-pharmacological methods for maintaining and improving cognitive function are also of great importance.

1. Chukanova AS, Chukanova EI. Comorbid patient in neurologist practice: possibilities of treatment. Consilium Medicum. 2019;21(2):53–58. (In Russ.) https://doi.org/10.26442/20751753.2019.2.190266.

2. Zakharov VV, Vakhnina NV, Gogoleva AG, Mezhmidinova SK. Diagnostics and treatment of chronic cerebral ischemia. Meditsinskiy Sovet. 2020;(8):36–45. (In Russ.) https://doi.org/10.21518/2079-701X-2020-8-36-45.

3. Weisman DSh. Mortality from cerebrovascular diseases in the Russian Federation before and during the COVID-19 epidemic: regional differences. Profilakticheskaya Meditsina. 2024;27(4):12–17. (In Russ.) https://doi.org/10.17116/profmed20242704112.

4. Верещагин НВ, Моргунов ВА, Гулевская ТС. Патология головного мозга при атеросклерозе и артериальной гипертонии. М.: Медицина; 1997.

5. Суслина ЗА, Варакин ЮЯ. Клиническое руководство по ранней диагностике, лечению и профилактике сосудистых заболеваний головного мозга. М.: МЕДпресс-информ; 2017. 352 с.

6. Zhitkova YuV. Clinical and etiological associations in chronic cerebral ischemia. Neurology, Neuropsychiatry, Psychosomatics. 2015;7(4):11–17. (In Russ.) https://doi.org/10.14412/2074-2711-2015-4-11-17.

7. Shishkova VN, Adasheva TV. Cronic cerebral ischemia and headache in patients in primary care physician’s practice. Nevrologiya, Neyropsikhiatriya, Psikhosomatika. 2021;13(1):131–137. (In Russ.) https://doi.org/10.14412/2074-2711-2021-1-131-137.

8. Bogolepova AN. The role of oxidative stress in the development of vascular cognitive disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2020;120(8):133–139. (In Russ.) https://doi.org/10.17116/jnevro2020120081133.

9. Парфенов ВА. Дисциркуляторная энцефалопатия и сосудистые когнитивные расстройства. М.: ИМА-ПРЕСС; 2017. 128 с.

10. Kovalchuk VV. Vascular Cognitive Impairment in Diabetes Mellitus. Understanding Features of Etiopathogenesis as Key to Improving Therapeutic Efficacy. Nervous Diseases. 2020;(3):3–13. (In Russ.) https://doi.org/10.24411/2226-0757-2020-12224.

11. Kamchatnov PR, Umarova HY. Chronic cerebral ischemia: treatment options. Spravochnik Poliklinicheskogo Vracha. 2013;(6):24–28. (In Russ.) Available at: https://elibrary.ru/sjhktv.

12. Кадыков АС. Хронические сосудистые заболевания головного мозга. Дисциркуляторная энцефалопатия. 4-е изд., перераб. и доп. М.: ГЭОТАРМедиа; 2020. 288 с.

13. Mendelevich EG. Chronic cerebral ischemia and dizziness. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2022;122(3):22–26. (In Russ.) https://doi.org/10.17116/jnevro202212203122.

14. Drapkina OM, Burns SA, Nikulina SYu, Solovieva EYu. Screening algorithm for predementia cognitive impairment in cardiovascular patients at a general practitioner’s appointment. Expert Consensus Statement. Cardiovascular Therapy and Prevention. 2024;23(10):4132. (In Russ.) https://doi.org/10.15829/1728-8800-2024-4132.

15. Parfenov VV. Improving the management of patients with a diagnosis of chronic cerebral ischemia. Meditsinskiy Sovet. 2020;(8):39–45. (In Russ.) https://doi.org/10.21518/2079-701X-2020-8-39-45.

16. O’Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L et al. Vascular cognitive impairment. Lancet Neurol. 2003;2(2):89–98. https://doi.org/10.1016/S1474-4422(03)00305-3.

17. Smith EE, O’Donnell M, Dagenais G, Lear SA, Wielgosz A, Sharma M et al.; PURE Investigators. Early cerebral small vessel disease and brain volume, cognition, and gait. Ann Neurol. 2015;77(2):251–261. https://doi.org/10.1002/ana.24320.

18. Jahno NN, Levin OS, Damulin IV. Comparison of clinical and MRI data in discirculatory encephalopathy. Message 2: cognitive impairment. Nevrologicheskii Zhurnal. 2001;6(3):10–18. (In Russ.) Available at: https://www.elibrary.ru/shsmnl.

19. Gusev EI, Chukanova EI. Modern pathogenetic aspects of the formation of chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2015;115(3):4–8. (In Russ.) https://doi.org/10.17116/jnevro2015115314-8.

20. Rakhmatullina EF, Kochergina OS, Khaibullina DK. Experience of the use of dipyridamole for secondary prevention of ischemic stroke. Meditsinskiy Sovet. 2022;16(23):52–58. (In Russ.) https://doi.org/10.21518/2079-701X2022-16-23-42-48.

21. Borodulina IV. Cognitive Rehabilitation. A Review. Comorbidity Neurology. 2024;1(2):41–49. (In Russ.) https://doi.org/10.62505/3034-185x-2024-1-2- 41-49.

22. Петрищев НН, Власов ТД. Физиология и патофизиология эндотелия. В: Петрищев НН, Власов ТД. Дисфункция эндотелия. Причины, механизмы, фармакологическая коррекция. СПб.: Изд-во СПбГМУ; 2003. 382 с. https://doi.org/10.17750/KMJ2015-659.

23. Shabrov AV, Galenko AS, Uspensky YuP, Loseva KA. Methods for diagnosing endothelial dysfunction. Bulletin of Siberian Medicine. 2021;20(2):202–209. (In Russ.) https://doi.org/10.20538/1682-0363-2021-2-202-209.